Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Graham, K. A. Articles by Harp, J. B. Search for Related Content PubMed Citation Articles by Graham, K. A. Articles by Harp, J. B. Atypical Neuroleptics Schizophrenia Spectrum Disorders

Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis

OBJECTIVE: Weight gain is a commonly observed adverse effect of atypical antipsychotic medications, but associated changes in energy balance and body composition are not well defined. The authors report here the effect of olanzapine on body weight, body composition, resting energy expenditure, and substrate oxidation as well as leptin, insulin, glucose, and lipid levels in a group of outpatient volunteers with first-episode psychosis. METHOD: Nine adults (six men and three women) experiencing their first psychotic episode who had no previous history of antipsychotic drug therapy began a regimen of olanzapine and were studied within 7 weeks and approximately 12 weeks after olanzapine initiation. RESULTS: After approximately 12 weeks of olanzapine therapy, the median increase in body weight was 4.7 kg, a significant increase of 7.3% from first observation. Body fat, measured by dual-energy x-ray absorptiometry, increased significantly, with a propensity for central fat deposition. Lean body mass and bone mineral content did not change. Resting energy expenditure, measured by indirect calorimetry, did not change. Respiratory quotient significantly increased 0.12 with olanzapine and was greatest in those who gained >5% of their initial weight. Fasting insulin, C-peptide, and triglyceride levels significantly increased, but there were no changes in glucose levels; total, high density lipoprotein, or low density lipoprotein cholesterol levels; or leptin levels. CONCLUSIONS: Olanzapine appears to have induced an increase in central body fat deposition, insulin, and triglyceride levels, suggesting the possible development of insulin resistance. The decrease in fat oxidation may be secondary or predispose patients to olanzapine-induced weight gain.

This article has been cited by other articles:

				O. Sentissi, J. Epelbaum, J.-P. Olie, and M.-F. Poirier Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review Schizophr Bull, November 1, 2008; 34(6): 1189 - 1199. [Abstract] [Full Text] [PDF]

				M. Fell, J. Neill, N. Anjum, L. Peltola, and K. Marshall Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats J Psychopharmacol, March 1, 2008; 22(2): 182 - 186. [Abstract] [PDF]

				N. Bozina, V. Medved, M. R. Kuzman, I. Sain, and J. Sertic Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients J Psychopharmacol, September 1, 2007; 21(7): 728 - 734. [Abstract] [PDF]

				G.D. Cooper, L.C. Pickavance, J.P.H. Wilding, J.A. HarroLd, J.C.G. HaLford, and A.J. Goudie Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities J Psychopharmacol, June 1, 2007; 21(4): 405 - 413. [Abstract] [PDF]

				H. Hosojima, T. Togo, T. Odawara, K. Hasegawa, S. Miura, Y. Kato, A. Kanai, A. Kase, H. Uchikado, and Y. Hirayasu Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia J Psychopharmacol, January 1, 2006; 20(1): 75 - 79. [Abstract] [PDF]

				S. Tighe and T. Dinan An overview of the central control of weight regulation and the effect of antipsychotic medication J Psychopharmacol, November 1, 2005; 19(6_suppl): 36 - 46. [Abstract] [PDF]

				R. I. G. Holt, C. Bushe, and L. Citrome Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol, November 1, 2005; 19(6_suppl): 56 - 65. [Abstract] [PDF]

				M. B. ISAAC and M. T. ISAAC Olanzapine and Weight Gain Am J Psychiatry, September 1, 2005; 162(9): 1764 - 1765. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us